Ga direct naar de productinformatie
a clear glass vial containing off-white powder, labeled ‘Gonadorelin 10 mg – Batch No.003 – 17-06-2025,’ sealed with a gray rubber stopper and matte aluminum cap, set against a soft beige background.”
1/2
Gonadorelin 10mg vial

Gonadorelin 10mg vial

€50,00 EUR
Belastingen inbegrepen.

                                   NOT FOR HUMAN CONSUMPTION

Gonadorelin is the synthetic form of endogenous gonadotropin-releasing hormone (GnRH, LHRH)—a decapeptide secreted in pulses by the hypothalamus. It binds GnRH receptors on pituitary gonadotrophs to trigger luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release, which in turn regulate sex-steroid production and gametogenesis. Clinically, gonadorelin is approved in several regions as a diagnostic agent for assessing pituitary gonadotroph function (e.g., delayed puberty, amenorrhea, hypogonadism). Therapeutically, pulsatile infusion can restore fertility in hypothalamic hypogonadism; continuous exposure desensitizes the receptor (the basis of long-acting GnRH-agonist therapy), but gonadorelin itself is short-acting.

Additional Benefits of Gonadorelin Now Under Investigation

Benefit Key take-aways
1 Physiologic ovulation in hypothalamic amenorrhea Pulsatile SC/IV delivery (q60–90 min) reconstitutes LH/FSH pulsatility, yielding mono-follicular ovulation with a low multiple-gestation and OHSS risk compared with exogenous gonadotropins. <br/><em>Fertility and Sterility; Human Reproduction</em>
2 Restoration of spermatogenesis in congenital/functional HH In men with GnRH deficiency (e.g., Kallmann) or functional hypothalamic suppression, pulsatile therapy initiates testicular growth and spermatogenesis, providing a physiologic alternative to hCG/hMG. <br/><em>Journal of Clinical Endocrinology & Metabolism; Andrology</em>
3 Diagnostic discrimination of hypothalamic vs pituitary disease Single-bolus GnRH testing (e.g., 100 µg IV) helps differentiate pituitary gonadotroph failure(blunted LH/FSH) from hypothalamic causes (delayed but present response). <br/><em>Endocrine Reviews; JCEM</em>
4 Luteal-phase optimization in restored cycles With pulsatile induction, luteal function is often adequate; when suboptimal, physiologic progesterone support can normalize implantation milieu while maintaining low hyperstimulation risk. <br/><em>Reproductive BioMedicine Online; Obstetrics & Gynecology</em>
5 Lower cumulative iatrogenic risks vs gonadotropins Physiologic follicular recruitment reduces multifetal pregnancy, cycle cancellation, and OHSS, potentially improving safety-per-pregnancy metrics in HH. <br/><em>Fertility and Sterility; Human Reproduction Update</em>
6 Functional hypothalamic amenorrhea (FHA) in athletes/stress In FHA refractory to lifestyle intervention, temporary pulsatile GnRH can re-establish cyclesand mitigate hypoestrogenic sequelae (bone, urogenital) without supraphysiologic gonadotropin exposure. <br/><em>Sports Medicine; Endocrine Connections</em>
7 Pubertal axis assessment In delayed or ambiguous puberty, GnRH testing—alone or with sex-steroid priming—improves diagnostic yield and risk-stratifies for progression vs pathology. <br/><em>Pediatrics; European Journal of Endocrinology</em>
8 Post-pituitary surgery surveillance Serial GnRH tests can track gonadotroph reserve during recovery after pituitary adenoma therapy, complementing basal gonadotropins and inhibin B/AMH. <br/><em>Pituitary; Clinical Endocrinology</em>
9 Research tool for frequency-coding biology Controlled pulse-frequency modulation (faster → LH-biased, slower → FSH-biased) enables study of gonadotropin subunit transcription and personalized induction paradigms. <br/><em>Nature Reviews Endocrinology; Molecular Endocrinology</em>

2. Molecular Mechanism of Action

2.1 Receptor Pharmacodynamics

Gonadorelin binds the GnRH (GNRHR) GPCR on pituitary gonadotrophs → Gαq/11–PLCβ–IP₃/DAG–Ca²⁺/PKCsignalling → exocytosis of pre-formed LH/FSH and transcriptional up-regulation of CGA, LHB, FSHB.

  • Pulsatile exposure preserves receptor responsiveness and frequency-codes LH vs FSH synthesis.

  • Continuous exposure leads to receptor desensitization/internalization and suppression of LH/FSH.

2.2 Down-stream Biology

Pathway Functional outcome Context
IP₃/Ca²⁺, PKC, ERK Acute LH/FSH release; gene transcription of gonadotropin subunits Pituitary
LH → theca/Leydig ↑ Androgen (substrate for estradiol; testosterone production) Ovary/testis
FSH → granulosa/Sertoli Folliculogenesis, aromatase; spermatogenesis support Ovary/testis
Steroid feedback E2/T, inhibin, progesterone fine-tune GnRH/LH/FSH HPG axis

3. Pharmacokinetics

  • Route: IV/SC for testing; pulsatile SC or IV via portable pump for therapy.

  • Onset/peak: LH rises within ~15–30 min of a bolus; FSH lag modestly longer.

  • Half-life: ~2–4 minutes (IV); short systemic exposure mandates pulsatile delivery for therapeutic use.

  • Clearance: Peptidase degradation; renal/hepatic peptide catabolism; no CYP interactions.

4. Pre-clinical and Translational Evidence

4.1 Female Hypothalamic Hypogonadism

Pulsatile GnRH achieves high ovulation and pregnancy rates with monofollicular cycles and very low OHSS, often favored when a physiologic approach is desired or when PCOS is absent.

4.2 Male Hypogonadotropic Hypogonadism

In congenital GnRH deficiency and functional HH, pulsatile therapy restores intratesticular testosterone, Sertoli cell function, and spermatogenesis; time-to-sperm varies by onset/severity and prior cryptorchidism.

4.3 Diagnostics

Standardized GnRH stimulation protocols assist in delayed puberty, amenorrhea, post-surgical pituitary assessment, and central precocious puberty (historically)—now often replaced by long-acting agonist tests where available.

5. Emerging Clinical Interests

Field Rationale Current status
Functional HA in athletes Reversible hypothalamic suppression; fertility desire Specialized centers use pulsatile therapy after lifestyle care
Personalized pulse-coding Titrate LH/FSH balance via frequency Under investigation with smart pumps
Oncofertility (post-therapy HH) Axis reconstitution after cranial RT/chemo Case-series/feasibility
Assisted reproduction adjuncts Physiologic trigger strategies and luteal support Niche, protocol-dependent

6. Safety and Tolerability

  • Common: Flushing, headache, transient lower abdominal discomfort; injection-site erythema with pumps.

  • Cycle risks (women): Low rates of multiples and OHSS compared with exogenous gonadotropins; monitor follicles/estradiol.

  • Men: Gynecomastia uncommon; monitor testicular volume, sperm parameters, and hematocrit as T normalizes.

  • Contraindications: Pregnancy, hormone-sensitive malignancy, uncontrolled pituitary disease, hypersensitivity to GnRH/analogs.

  • Operational: Pump therapy requires aseptic technique, catheter care, and adherence.

Comparative safety matrix

Concern Gonadorelin (pulsatile) Exogenous gonadotropins (hMG/FSH+hCG) Long-acting GnRH agonists
Physiologic LH/FSH pattern Yes (pulse-coded) No (pharmacologic) No (suppression)
Multiples/OHSS in induction Low Higher N/A (suppressive)
Convenience Pump/catheter burden Injections but simpler Injections monthly/3-monthly
Typical use HH fertility induction; diagnostics Broad ovulation induction; ART Suppression (endometriosis, CPP, prostate Ca)

7. Regulatory Landscape

  • Approved indication (many regions): Diagnostic testing of pituitary gonadotroph function (e.g., single-dose IV/SC).

  • Therapeutic use: Pulsatile GnRH for hypothalamic hypogonadism–related infertility practiced in specialized centers; availability varies by device access and local regulation.

  • Not indicated as chronic suppressive therapy—long-acting analogs fill that role.

8. Future Directions

  • Smart pumps & closed-loop dosing using real-time LH feedback to optimize pulse frequency and minimize monitoring.

  • Integration with lifestyle/energy-availability restoration in FHA to shorten time-to-menses and protect bone.

  • Biomarker panels (kisspeptin, inhibin B/AMH) to refine diagnosis and prognostication before committing to pump therapy.

  • Male protocols combining pulsatile GnRH with hCG/FSH to accelerate spermatogenic recovery in select phenotypes.

Selected References

  • Crowley W.F., Filicori M., et al. Pulsatile GnRH therapy in hypothalamic amenorrhea and hypogonadotropic hypogonadism. Journal of Clinical Endocrinology & Metabolism; Fertility and Sterility.

  • Hall J.E., Hayes F.J. Physiology of GnRH pulse frequency and gonadotropin synthesis. Endocrine Reviews; Molecular Endocrinology.

  • Bouchard P., et al. Diagnostic use of the GnRH (gonadorelin) stimulation test. JCEM; Pediatrics.

  • Martin K.A., et al. Functional hypothalamic amenorrhea—diagnosis and management. Human Reproduction Update; Endocrine Connections.

  • Pitteloud N., et al. Kallmann syndrome and congenital GnRH deficiency—restoration of fertility. Andrology; JCEM.

  • Tarlatzis B.C., et al. Ovulation induction strategies and OHSS prevention. Human Reproduction; Reproductive BioMedicine Online.

  • Melmed S., et al. Pituitary disease evaluation and post-surgical testing. Clinical Endocrinology; Pituitary.

  • Plant T.M., Marshall J.C. Puberty and GnRH neuroendocrinology. Endocrine Reviews.

  • Welt C.K., et al. Luteal support and implantation after physiologic induction. Obstetrics & Gynecology; Fertility and Sterility.